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ABSTRACT: Cell-surface functionality is largely programmed by
genetically encoded information through modulation of protein
expression levels, including glycosylation enzymes. Genetic tools
enable control over protein-based functionality, but are not easily
adapted to recruit non-native functionality such as synthetic
polymers and nanomaterials to tune biological responses and
attach therapeutic or imaging payloads. Similar to how polymer−
protein conjugation evolved from nonspecific PEGylation to site-
selective bioconjugates, the same evolution is now occurring for
polymer−cell conjugation. This Viewpoint discusses the potential
of using metabolic glycan labeling to install bio-orthogonal reactive
cell-surface anchors for the recruitment of synthetic polymers and
nanomaterials to cell surfaces, exploring the expanding therapeutic
and diagnostic potential. Comparisons to conventional approaches that target endogenous membrane components, such as
hydrophobic, protein coupling and electrostatic conjugation, as well as enzymatic and genetic tools, have been made to highlight the
huge potential of this approach in the emerging cellular engineering field.
Cell surface re-engineering with small molecules, nano-particles, and polymers has expanded the repertoire of
tools used in biological sciences and modern medicine,
increasing our understanding of fundamental biological
processes and expanding the arsenal of future cell-based
therapies. Recruitment of natural and synthetic polymers offers
an attractive opportunity to install non-native functionality
directly to the cell membrane, enabling modulation of cell−cell
and cell−microenvironment interactions along with targeted
delivery of therapeutic agents.1−5 Recently, receptor-engineer-
ing of cell surfaces using multiplex genome editing has
emerged as a potent treatment in oncology, such as chimeric
antigen receptors (CAR),6,7 reaching the clinic, despite their
challenging manufacturing and transport processes.8,9 For
example, lentiviral and γ-retroviral transduction delivery of
transgenes can lead to a variable copy number, semirandom
integration, heterogeneous expression, and insertional muta-
genesis.10−13 Re-engineering cellular interfaces with synthetic
polymers provides an alternative platform for potential
advancement of fields, including cell-based therapies to alter
cellular signaling pathways, mask surface antigens, and install
unnatural functionality through recruitment of bioactive
macromolecules,14−16 drug cargoes,5,17 and imaging agents.4,18
Polymer conjugation to cell surfaces has so far focused on
targeting endogenous membrane components using non-
specific approaches including covalent conjugation to amino
acid residues and electrostatic interactions with the negatively
charged cell membrane.19−21 Such nonspecific conjugation
approaches are straightforward but possess caveats for the
production of polymer−cell hybrids with functional impor-
tance, including lack of compatibility with cell culture
conditions, inadaptability for in vivo labeling, inhomogeneous
labeling of cell populations, and cell death. Alternatively,
membrane insertion of lipidated glycopolymers is particularly
appealing for noninvasive remodeling of the glycocalyx to
regulate its structural, metabolic, and recognition roles, but the
short cell surface retention capabilities may limit its potential
applications.22−24
Metabolic oligosaccharide engineering (MOE) has emerged
as an alternative approach to re-engineer the glycocalyx,
allowing the installation of exogenous chemical receptors to
glycan residues by “hijacking” the glycan biosynthetic pathway.
Addition of biorthogonal, cell surface bound reactive units in
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this manner supplies “anchor” sites for targeted in vitro and in
vivo delivery of abiotic therapeutic components to the cell
surface.25,26 Due to the expanding potential therapeutic
benefits of cell−polymer hybrids, polymer cell surface re-
engineering can be considered the next evolution from
polymer−protein conjugation; a field that progressed from
nonspecific conjugation techniques (e.g., targeting lysine and
cysteine side chain groups) to site-selective modification of
non-natural amino acids.27,28 As with proteins, this advance-
ment is underpinned by improvements in regio- and chemo-
selective “bio-orthogonal” coupling reactions.29
Considering the above, this Viewpoint will highlight
advances in using MOE as a versatile tool for the recruitment
of polymeric nanoscale materials such as synthetic polymers,
oligonucleotides, and nanoparticles to the cellular interface;
exploring the expanding therapeutic and diagnostic potential in
biomolecule capture, drug delivery, microfabrication, and
immune therapy. Alternative methods to modify glycans (e.g
boronic acids) are not included here, which have previously
been reviewed.30,31 We highlight the opportunities in synthetic
polymer/materials chemistry in the context of taking the next
steps from polymer−protein to polymer−cell engineering.
Metabolic oligosaccharide engineering (MOE), a technique
pioneered by Bertozzi and co-workers,26 allows the installation
of exogenous glycans into the cellular glycocalyx through
chemically modified versions of native sugars. These unnatural
sugars “hijack” the promiscuous biosynthetic or salvage
pathways of endogenous glycans, allowing the installation of
biorthogonal functional groups onto the cell surface, Figure 1,
and hence recruitment of additional functionality. MOE has
enabled the installation of sugars modified with ketone,26
azide,25 alkyne,32 thiol,33 diazirine,34 cyclopropene,35 alkene,36
isonitrile,37 diazo,38 and norbornene36 functional groups into
plants,39 bacteria,40−42 and yeast,43 along with mice,44 rats,45
zebrafish,46 Caenorhabditis elegans,47 and Drosophila mela-
nogaster.48 Unnatural N-acetyl mannosamine (ManNAc)
derivatives hijack the promiscuous sialic acid biosynthetic
pathway, providing the highest abundance of cell surface
coverage with biorthogonal functional groups compared to all
other unnatural glycan analogues in multiple cell types,
including hMSCs, hippocampal, CHO, and MDA-MB-
231.49−52 Cell surface labeling is often achieved following 72
h of incubation with low concentrations of unnatural sugar (50
μM). Alternative unnatural sugar analogues include N-acetyl
glucosamine (GlcNAc), N-acetyl galactosamine (GalNAc),
and fucose that, in addition to sialic acids, are overexpressed in
certain diseases and may be suitable alternatives to ManNAc
for cell surface labeling, depending on glycan overexpression
levels and the desirability to label, or avoid labeling, the range
of glycans mentioned in Figure 1.53 Glycans modified with an
azide group, such as N-azidoacetylmannosamine-tetraacetate
(Ac4ManNAz), are the most widely used glycan for targeted in
vitro and in vivo delivery of nanoscale materials due to their
synthetic simplicity, commercial availability, and advances in
copper-free “click” azide−alkyne reactions, providing a chemo-
selective and cytocompatible conjugation approach that can
occur rapidly under physiological conditions.50 As glycosyla-
tion is a post-translational modification procedure, exogenous
target receptors can be introduced to multiple cell types with
MOE without resorting to gene editing approaches. Targeted
in vivo delivery of Ac4ManNAz can be accomplished
intratumorally,54 intraperitoneally,44,55 or even intravenously
using caged Ac4ManNAz derivatives requiring endogenous
enzyme cleavage for intracellular uptake, such as histone
deacetylase and cathepsin L overexpressed in cancerous cells56
or caspase-3/-7 in live apoptotic cells,57 or ligand-targeted
liposomes to target expressed or up-regulated cell surface
receptors.54,58 In addition, Xie et al. demonstrated successful
incorporation and probing of exogenic azide receptors on mice
brain sialoglycans via liposomal delivery of 9-azido sialic acid
(9AzSia), highlighting the true in vivo labeling potential of
MOE, even surpassing the blood−brain barrier.56
Figure 1. Metabolic oligosaccharide engineering with unnatural derivatives of glycan’s allows “hijacking” of biosynthetic pathways of endogenous
glycan analogues to install biorthogonal handles (R1) for chemoselective ligation. R2 = OH or Ac.
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In the following paragraphs, we survey the literature and
show the current progress and potential of MOE for
recruitment of synthetic and natural polymers, as well as
nanoparticles to living cell surfaces, with comparisons to
current strategies for polymer/nanomaterial conjugation.
Nonmetabolic polymer−cell hybrid examples: Polymer
conjugation to endogenous cell membrane components has
shown potential in the masking of cell surface antigens and
modulation of biological functions. For example, “stealthy”
erythrocytes have been produced by passive installation of
polyethylene glycol (PEG) into the cell membrane or by
covalent conjugation to membrane proteins to evade immune
recognition and reduce malaria parasite binding.59−63 Similarly,
islet cell encapsulation can prevent xenogenic and human
embryonic stem cell (hESC)-derived allogenic transplant
rejection through modulation of the immediate blood
inflammatory response and blocking of host immune cells by
natural (heparin,64,65 thrombomodulin,66 and urokinase)67,68
or synthetic (PEG,69−72 poly-L-lysine,19,73,74 or polyacry-
lates)75−77 polymer conjugation to the cell membrane, through
covalent attachment to amino acid residues or polycation
electrostatic interactions, while permitting glucose responsive
secretion for treatment of type 1 diabetes.
However, the full potential of recruiting polymers to the cell
membrane is not merely to provide physical isolation from the
immune system, but also to modulate biological processes and
functions. Bertozzi and co-workers pioneered glycocalyx
remodeling with lipid-terminated mucin mimetic glycopol-
ymers to passively insert glycan epitopes, with no loss of
membrane function or mobility.78 For example, the installation
of sialylated glycopolymers onto Jurkat cells, CD34+
hematopoietic stem cells (HSCs), and pig aortic epithelial
cells enables recruitment of sialic acid-binding immunoglobu-
lin-like lectin 7 (Siglec-7), a cell surface receptor containing a
cytosolic immunoreceptor tyrosine-based inhibitory motif able
to attenuate a natural killer (NK) cell response.24 Godula and
co-workers revealed that lipidated synthetic neoproteoglycans,
mimetics of native sulfated glycosaminoglycans (HS GAGs),
can recruit fibroblast growth factor 2 (FGF2) to induce neural
specification downstream signaling pathways in embryonic
stem cells (ESCs) deficient in exostosin, a key glycotransferase
enzyme required for native HS GAGs assembly.79 Similarly, rat
cortical neurons engineered with chondroitin HS GAG
conjugated liposomes, for membrane fusion, have been used
to enhance nerve growth factor-mediated signaling and
promote neural outgrowth in rat cortical neurons by activating
neurotrophin-mediated signaling pathways.23
Metabolic recruitment of synthetic polymers: Although re-
engineering cellular interfaces has huge potential for cell-based
therapies, targeting endogenous cell membrane components
presents challenges limiting its translational application
including cytotoxicity, short membrane retention time, and
lack of specificity.20 As previously discussed, the use of MOE
has various advantages including cytocompatibility, a panel of
biorthogonal functional groups to select from and universal
applicability across a range of cell types, providing the ideal
platform for polymer conjugation. Tomaś et al. demonstrated
that MOE on adenocarcinomic human alveolar basal epithelial
(A549) cells with Ac4ManNAz allows chemoselective recruit-
ment of strained alkyne-terminated poly(N-hydroethyl acryl-
amide) (pHEA) polymers, Figure 2.80,81 Altering Ac4ManNAz
dosage enabled modulation of azido glycan incorporation to
the cell surface for immobilization of reversible addition−
fragmentation transfer (RAFT) synthesized telechelic polymers
bearing an azide-targeting [dibenzocyclooctyne (DBCO)] unit
and a model cargo, fluorescein. Therefore, Ac4ManNAz dosage
can be varied to prevent polymer oversaturation of target
exogenous receptor sites or reduced to restrict polymer
conjugation; compared to targeting endogenous membrane
components such as amino acid residues. Crucially, cell surface
reengineering with synthetic materials was completed in a
highly controllable, dose- and molecular weight-dependent
manner, with flow cytometry revealing homogeneous labeling
of over 95% of cell populations; evident by narrow Gaussian
distributed cell populations. Thus, polymer grafting densities
using MOE can be fine-tuned to achieve optimum coverage for
specific applications where it, and molecular weight depend-
ence, has functional importance (i.e., linkers to prevent
cytotoxicity of charged species,82 enhancing the activity of
enzymes,83 attachment of large biomolecules).84 The robust
covalent linkages developed between azido labeled sialic acid
residues and pHEA polymers remained stable for over 72 h,
surviving multiple mitotic divisions. Loss of cell surface bound
polymer was attributed to polymer passing to daughter cells
during mitosis and potentially membrane turnover processes;
however, commenting on such complex processes is difficult as
the time scale of glycocalyx recycling is highly variable.85,86
A549 cells untreated with Ac4ManNAz demonstrated minimal
nonspecific binding of pHEA; thus, MOE cells re-engineered
Figure 2. Metabolic glycoengineering with Ac4ManNAz provides
bioorthogonal azide handles for cell-surface recruitment of pHEA
polymers bearing DBCO and abiotic fluorescent cargos (green).
Adapted from ref 81 and reproduced with permission. Copyright 2019
American Chemical Society.
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with synthetic polymers do not require purification to obtain
homogeneously labeled cells due to high labeling efficiencies
and selectivity, providing a powerful tool to introduce cell-
surface receptors and capture abiotic components for the
development of polymer−cell hybrids.
Conventional versus metabolic approaches for polymer
recruitment: To demonstrate the potential of MOE for
synthetic polymer re-engineering of cell surfaces, comparisons
to nonspecific polymer grafting approaches, especially those
already discussed as having potential therapeutic value as
nonmetabolic polymer-cell hybrid examples, must be consid-
ered, Figure 3. For example, one of the most widely exploited
moieties for polymer grafting to mask cell surface antigens are
the nucleophilic (primarily amine or thiol) side chains of
amino acids with, for example, N-hydroxyl-succinimidyl ester
(NHS) functionalized polymers, Figure 3C.60,87,88 However,
labeling heterogeneity (i.e., production of homogeneously
polymer-labeled cell populations) and perturbation of vital
protein activity remain drawbacks, along with variable surface
retention.89 Specificity and homogeneity can be improved
through site-specific introduction of non-natural amino acids
to avoid targeting amino acids with vital functional
importance; however, such approaches rely on genetic
alterations90 or metal catalysts to chemically modify
endogenous amino acid residues.91−94 Hawker and co-workers
attempted an alternative grafting-from approach whereby
Jurkat T cells were modified with NHS-functional RAFT
agents for photoinduced electron transfer-reversible addition−
fragmentation chain-transfer polymerization directly from the
cell surface.95 Poor cell viability was observed due to
mammalian cell sensitivity to mechanical and chemical
environmental changes, so lipid insertion of RAFT agents
was a necessary alternative to preserve cytocompatibility.
While successful, polymer conversions and heterogeneous
labeling remained an issue. Grafting-from approaches are also
limited due to unwanted side reactions with protein functional
groups, protein denaturing, oxygen radical formation, and
cytotoxic catalyst requirements, restricting the capability to
maintain normal cell culture conditions.95,96
Alternative noncovalent approaches include electrostatic
deposition of polyelectrolytes to the intrinsically negatively
charged peripheral cellular membrane using layer-by-layer
(LbL) assembly, Figure 3A.74 However, direct deposition of
polycations remains a huge challenge due to rapid and
extensive membrane damage via polycation pores97−99 or
acid-catalyzed hydrolysis of cell membrane lipidic phosphoest-
er bonds.100 Controlling polycation cytotoxicity remains
problematic as various factors can influence cell death,
including polyions’ functional groups, intracellular polymer
uptake,101,102 and polymer surface charge density.103,104 In
comparison to polymer grafting to proteins and electrostatic
deposition of polymers, the metabolic glycan polymer labeling
approach (Figure 3D) demonstrates that MOE allows rapid,
homogeneous, and efficient polymer conjugation to occur
under native biological conditions, with cells retaining ∼90% of
viability.81 Furthermore, the use of exogenous azide receptor
sites allows selective installation of polymeric materials with no
cellular function deterioration and is universally applicable
across a range of cell types.
As previously discussed, hydrophobic insertion of polymers
provides a noninvasive, simple, and cytocompatible approach
to introduce functionality and has been used to probe and
modulate the functional importance of the glycocalyx with
synthetic polymers.23,79 However, passive insertion of lipid-
based polymers is limited by rapid dissociation times, with
lipid-glycoconjugates possessing a surface half-life of 4−8 h79
and the complete dissociation of the synthetic PEG-lipid
occurring within 3 h due to intrinsic membrane turnover
processes, Figure 3B.89,105 Synthetic polymers installed onto
exogenous azide receptors produce robust covalent linkages
that survive multiple mitotic divisions, with the cell-surface
bound polymer remaining beyond 3 days, a similar time scale
compared to polymer−protein conjugation approaches,20 and
the cell surface bound polymer is passed onto daughter cells.81
In addition, lipid-based approaches lack selectivity, only
allowing labeling of the cell membrane, whereas careful
Figure 3. Comparisons between nonspecific conjugation and
metabolic cell labeling approaches. Confocal images of live HEK293
cells nonspecifically labeled with (A) poly(ethylene imine), (B) PEG-
lipid, and (C) PEG-NHS (from ref 88); and (D) live A549 cells
metabolically labeled with Ac4ManNAz and pHEA-DBCO (from ref
81). All images were taken both immediately and 24 h following
polymer grafting to assess surface retention. Confocal images: green =
fluorescent polymer; blue = nuclear DAPI stain. Criteria: green tick =
positive outcome; amber tick = results vary; red cross = negative
outcome. (A)−(C) are adapated from ref 88 with permission.
Copyright 2008 Elsevier. (D) is adapted with permission from ref 81.
Copyright 2019 American Chemical Society.
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selection of unnatural sugars can allow (or avoid) labeling of a
specific range of glycans (e.g., mucin-type O-glycans);106
however, it should be noted that MOE is uneasily adaptable to
label individual glycoproteins. Thus, metabolic glycoengineer-
ing offers clear advantages over conventional polymer
conjugation approaches in cytocompatibility, specificity,
robustness, and stability.
Enzyme-mediated cell surface engineering provides an
alternative approach for more selective candidate protein/
molecular conjugation.107 Enzymes developed to recognize
and selectively cleave cell membrane peptide sequences
include transglutaminases,108,109 glycotransferases and hydro-
lases allowing subsequent site specific conjugation of abiotic
materials.110−112 However, enzymes, such as Transpeptidase
Sortase A (“sortagging”),113 suffer from reaction reversibility
and self-competition.114 In contrast, MOE with unnatural
sugars provide the advantage of universal applicability across
multiple cell types, with a plethora of functional groups for
material capture.
Biomedical and biotechnological applications of MOE
with polymers: The versatility of exploiting cell surface
metabolic labels offers opportunities in a range of biotechno-
logical and biomedical fields, where precision conjugation can
introduce functionality to cells. Tomaś and Gibson recruited
pHEA functionalized with DBCO and biotin to capture
streptavidin-cyanine5 (Cy5) as a simple demonstration of how
polymers can be easily adapted to capture biomolecules.81
Biomolecule capture utilizing MOE has also been extended to
antibody immobilization, presenting potential for immunomo-
dulation of the innate immune system. Uvyn et al. installed
antibody recruiting polymers (ARPs) consisting of RAFT-
synthesized pentafluorophenyl acrylate (PFPA) polymers
functionalized with DBCO, a fluorescent marker and DNP
onto metabolically glycoengineered Jurkat T cells to
successfully capture anti-DNP monoclonal antibodies.115
This approach was translatable to metabolically labeled
mouse 4T1 spheroids, allowing anti-DNP antibodies to be
captured with good penetration depth. Natural killer (NK) cell
and macrophage activation rely on antibody Fc-domain
recognition by types I and II Fc receptors; therefore, capturing
antibodies in this manner demonstrates potential to induce
innate immune cell responses.116
In addition to capturing biomolecules, Shi et al. demon-
strated that metabolic glycoengineering of cellular interfaces
allows spatiotemporal control over cell−cell interactions
through installation of photoswitchable polymers, Figure
4.117 MCF-7 cells treated with Ac4GalNAz, to label mucin-
type O-linked glycoproteins, allowed conjugation of alkynyl-
PEG-β-Cyclodextrin (β-CD) using copper-catalyzed azide
alkyne cycloaddition (CuAAC), Figure 4a. Upon addition of
azobenzene-PEG-azobenzene (azo-PEG-azo) cell aggregation
was observed due to the high binding affinity between β-CD
and trans-azobenzene. This homobifunctional cross-linking
agent mediated aggregation was reversed by conversion of
trans-azobenzene to its cis form and vice versa using UV and
visible light sources. Using a similar strategy, HeLa cells and
peripheral blood mononuclear cells (PBMCs) treated with
Ac4GalNAz and alkynyl-PEG-β-CD were used to capture azo-
MUC1 aptamers for controllable targeting of mucin 1 protein
expressed on epithelial cancer cells (MCF-7; MUC 1+)
inducing cell−cell adhesion and enhancing the cytotoxic effects
of PBMCs toward MCF-7 cells (Figure 4b). This clearly shows
the potential of metabolic glycoengineering for immune
therapy and to promote the future understanding of contact-
dependent cell communication. MOE can also control cellular
interactions to capture cells onto biomaterials including native
extracellular matrices,118 polymer nanofibrous scaffolds,119 and
hydrogels120 for tissue regeneration and repair or controlling
cell adhesion for diagnostic applications; however, this is
beyond the scope of this review.
Polymeric nanoparticle delivery via metabolic glycoengin-
eering: Nanoparticles have emerged as delivery carrier tools
Figure 4. Heterolytic cell adhesion with MOE. (A) Cyclodextrin
conjugation to cell surfaces using MOE; (B) recruitment of
photoactive azobenzene MUC1 aptamers to Hela (green) and
PBMC (blue) cell surfaces for subsequent photoswitchable adhesion
to MCF-7 cells (red) expressing mucin 1. Heterolytic adhesion
enhances cytotoxicity of PBMCs toward MCF-7 cells. Scale bar = 50
μm. Figure is adapted with permission from ref 117. Copyright 2016
SpringerNature.
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for imaging and drug delivery for both diagnostics and therapy.
However, targeted delivery to organs, tissues, and cellular
locations remains a challenge, especially with the efficacy of the
enhanced permeation and retention (EPR) effect being
questioned.121 Attempts to enhance nanoparticle accumulation
at disease sites, including altering physical and surface
properties (size or shape), as well as introducing targeting
biomolecules (antibodies, aptamers, or peptides), have had
insufficient success for clinical use.122,123 Endogenous receptor
sites are limited; thus, the use of specific targeting moieties
results in nanoparticle saturation, preventing successful
accumulation. Metabolic glycoengineering allows a controlled
installation of exogeneous biorthogonal receptors and, as has
already been discussed, in vivo labeling is possible to install
such receptor targets, removing the previously discussed
caveats of conventional approaches. Here, we discuss the
imaging, drug delivery, and therapeutic opportunities provided
by using MOE for the recruitment of polymeric nanoparticles.
In vivo nanoparticle imaging: Initially, in vivo nanoparticle
delivery using MOE relied on intratumoral injection of
Ac4ManAz into xenograft mice models bearing A549 tumors.
Exogenous azide receptors allowed selective accumulation of
intravenously injected DBCO functionalized PEGylated lip-
osomes (DBCO-PEG-Lipo) with incorporated Cy5-lipid to
tumor target sites with minimal nonspecific binding to azido
untreated tumors.124 However, intratumoral pretreatment with
Ac4ManAz is impractical for clinical translation as the exact
location/dimensions of tumor is often unknown, thus Kim and
co-workers proposed a two-step tumor targeting strategy.125
First, intravenous delivery of Ac4ManNAz was achieved by
loading into glycol chitosan nanoparticles (Ac4ManNAz-
CNPs), synthesized by conjugation of 5β-cholanic acid groups
to a glycol chitosan backbone. In vitro, Ac4ManNAz-CNPs
demonstrated cytocompatibility and universal applicability on
multiple cell lines, regardless of surface heterogeneity, and
revealed similar labeling capabilities to free Ac4ManNAz; thus,
nanoparticle encapsulation of Ac4ManNAz allows successful
delivery without limiting uptake. Intravenous administration of
Ac4ManNAz-CNP in A549 tumor-bearing mice demonstrated
high accumulation of azides at tumor sites by EPR effect of
nanosized carriers. Introducing exogenous receptors removes
limitations arising from receptor-binding molecules that target
limited endogenous receptors and are influenced by tumor
heterogeneity. Second, folate bicyclo[6.1.0]nonyne (BCN)-
modified and chlorin e6 (Ce6)-loaded CNPs (BCN-Ce6-
CNPs), labeled with fluorescein isothiocyanate, were intra-
venously injected into tumor-bearing mice pretreated with
Ac4ManNAz-CNP for copper-free “click” reaction. Targeted
accumulation of BCN-Ce6-CNPs in the tumor tissue of
Ac4ManNAz-CNP treated mice increased over time, demon-
strating tumor targeting capabilities, long blood circulation
time, and ease of tumor vessel penetration. Laser irradiation of
mice treated with Ac4ManNAz-CNP and BCN-Ce6-CNP
induced the photodynamic therapeutic properties of Ce6
resulting in tumor growth suppression, even 21 days after
irradiation, showing that this two-step metabolic glycoengin-
eering and nanoparticle accumulation strategy could be
successfully used for tumor therapy.
Similarly, metabolic glycoengineering allows in vivo targeted
delivery of small molecules56 and also metal-based nano-
particles possessing both imaging and photodynamic proper-
ties for photothermal therapy, allowing accurate and targeted
thermal ablation of solid tumors.126,127 Although another
prime example of the therapeutic efficacy of metabolic
glycoengineering for nanoparticle delivery, these examples are
beyond the scope of this viewpoint.
Nanoparticle tracking is also fundamental for the advance-
ment of stem cell-based therapies, aiding in the understanding
of their biodistribution and local microenvironment. However,
conventional tracking technologies are not effective for
heterogeneous stem cells with low endocytic capacity. Lee et
al. demonstrated that MOE of human mesenchymal stem cells
(hMSCs) with Ac4ManNAz (10−20 μM) allows the
introduction of azide receptors with no alterations to function,
viability, surface markers, or oncogenic gene expression levels,
for subsequent controllable, efficient (almost 100%), and
homogeneous delivery of imaging agents (Cy5.5, iron and
gold) using BCN-CNPs (Figure 5).49 Particle uptake occurred
rapidly (6 h) and remained internalized for up to 5 days in
vitro, revealing the successful distribution into daughter cells
through cytokinesis (Figure 5B). Dorsal subcutaneous
Figure 5. (A) BCN-CNPs are self-assembled under aqueous
conditions possessing imaging agents (Cy5.5, iron and gold) and a
strained alkyne for (B) cell surface binding and internalization by
hMSCs. (C) Subcutaneous implantation into mice allowed non-
invasive optical, MR, and CT stem cell tracking. Figure adapted with
permission from ref 49. Copyright 2017 Elsevier.
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implantation of BCN-CNP-Cy5.5-labeled hMSCs pretreated
with Ac4ManNAz into nude mice allowed noninvasive in vivo
stem cell tracking of as little as 1000 cells for up to 15 days,
with a direct proportionality between fluorescence intensity
observed at the implanted site and hMSC cell number
administered (Figure 5C). The long-retention capabilities of
BCN-CNP-Cy5.5 surpasses conventional nanoparticle-based
probes in minimizing the risks of in vivo false imaging caused
by exocytosis of imaging agents, followed by nonspecific
uptake of nearby normal cells or macrophages. Similarly,
cellular uptake of BCN-CNP-IRON and BCN-CNP-GOLD
particles into Ac4ManNAz labeled hMSCs were subcuta-
neously implanted into dorsal regions of mice, demonstrating
potential usage in deep tissue tracking of stem cells using MRI
or micro CT scanners (Figure 5C). This noninvasive stem cell
imaging technology demonstrates that metabolic glycoengin-
eering allows prolonged in vivo stem cell tracking with diverse
imageable nanoparticles to obtain high spatial resolution for
future stem cell therapy applications.
Nanoparticle drug delivery: Kim and co-workers have
shown the potential that metabolic glycoengineering holds for
in vivo capturing of nanoparticles as imaging agents, but also
possible opportunities as drug delivery systems. Initial studies
conducted by Iwasaki et al. confirmed that recruitment of 2-
methacryloyloxyethyl phosphorylcholine (MPC) polymer
nanoparticles, functionalized with hydrazide groups (PMBH),
could be used to deliver immobilized anticancer drugs
(Doxorubicin (DOX) and paclitaxcel (PAX)) in vitro to
human uterine cervical cancer (HeLa) cells treated with N-
levulinoylmannosamine (ManLev) to install cell surface bound
ketone glycans.128 Nanoparticle uptake via endosomal path-
ways provided controlled release of DOX over 48 h with
approximately 60% of cells died with 3 days of cultivation.
Similarly, PAX-loaded nanoparticles reduced ManLev-treated
Hela cell viability by 50% within 3 days of initial culture. Direct
addition of free DOX, DOX-PMBH, free PAX, or PAX-PMBH
lead to minimal decreases in cell viability; thus, confirming
metabolic glycoengineering possesses delivery capabilities for
cell impermeable chemotherapeutic small molecules.
MSCs naturally traffic toward primary tumors and
metastases in response to inflammatory signals, making them
ideal candidates for therapeutic and diagnostic tools. Layek et
al. devised an approach to utilize metabolic glycoengineering of
hMSCs to express exogeneous azide receptors for nanoparticle
capture, internalization, and subsequent use as an in vivo drug
delivery release system (Figure 6).129 Initially, mice bearing
subcutaneous A549-Luc lung tumors were dosed intravenously
with Ac4ManNAz treated MSCs (MSC-Az) labeled with a
DBCO-Cy5.5 dye. Tumor-selective accumulation of MSC-Az
was detectable for 10 days, whereas in tumor-free animals,
fluorescence detection was primarily in the clearance organs
such as liver and spleen. Tumor tropism of glycoengineered
MSCs-Cy5.5 was also observed after intraperitoneal injection
into MA148-Luc ovarian tumor bearing mice for 4 weeks with
no fluorescence in brain, lungs, spleen, kidneys, and heart,
Figure 6A. Intraperitoneal delivery of PAX encapsulated within
DBCO-functionalized poly(lactide-co-glycolide) (PLGA)
nanoparticles (DBCO-PLGA-PAX) was subsequently demon-
strated, targeting orthotopic ovarian tumors pretreated with
intraperitoneal injection of MSC-Az (Figure 6B). DBCO-
PLGA-PAX nanoparticles were detected within 15 min and
demonstrated enhanced tumor targeting and growth inhibition
compared to control saline treated tumors (Figure 6B).
Although delivery using MSCs can be completed through
gene alterations for protein/peptide-based therapeutics, small
molecules cannot be easily adapted, demonstrating how
metabolic glycoengineering of cell surface receptors provide a
simple and practical approach compared to gene therapies.130
Microfabrication: Briefly, we summarize the current status
of MOE’s application for the recruitment of DNA aptamers
within microfabrication and for controlling 3D microtissue
interactions. Microfabrication, a technique used to generate
patterns of cells on surfaces, conventionally relies on universal
endogenous cell adhesion receptors, such as integrins,
preventing simultaneous adhesion of multiple cell types with
high specificity and pattern reproducibility on a single
surface.131 Previously, DNA−polymer hybrids have been
grafted to the cell surface to encapsulate multiple cellular
organisms,132 alter intercellular adhesion and interac-
Figure 6. (A) Metabolically glycoengineered stem cells were labeled
with DBCO-Cy5.5 and injected intraperitoneally into MA148-Luc
ovarian tumor bearing mice to determine tumor tropism capabilities.
Tumor-free mice are shown as controls. (B) Intraperitoneal injection
of metabolically labeled stem cells was completed again, but followed
by intraperitoneal injection of DBCO-PLGA-PAX nanoparticles with
all relevant controls. Tumor growth and mice survival were measured
over 65 days (n = 4). Figure adapted with permission from ref 129.
Copyright 2016 Elsevier.
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tions,133,134 and capture primary cells135 in an attempt to
mitigate caveats of microfabrication with universal cell
adhesion moieties. However, DNA aptamer conjugation
often relies on NHS coupling to membrane proteins which,
as previously discussed, can perturb vital protein function.
Chandra et al. demonstrated that “DNA barcoding” could be
achieved using MOE to attach phosphine-ssDNA onto
Ac4ManNAz treated Jurkat cells, enabling patterning onto Au
pads with complementary ssDNA strands.136 Microfabrication
in this manner allowed subpopulations of Jurkat cells with
different ssDNA and cytosolic dyes to be selectively patterned
onto Au pads with two complementary ssDNA for over 25 h,
demonstrating specificity, even within the same cell type.
Similar results were obtained when applied to adherent cell
line Chinese Hamster Ovary (CHO) and HEK cells ensuring
the potential widespread use of this approach, for micro-
fabrication of both suspension and adherent lines, providing an
attractive means to control adhesion properties of living cells.
Douglas et al. further expanded on this work, demonstrating
that DNA barcoding allows capturing of cell cocultures within
microfluidic systems, consisting of ssDNA-functionalized
glass,137 in desired microscale patterns with robust linkages
withstanding lateral shear forces over 5-fold that of
physiological levels for any application requiring intact cells
in flow systems.138,139 Thus, microfabrication advancements
using MOE provide a universal approach for patterning cell
cocultures, with the potential to develop cellular array
microfluidic devices with integrated microelectrodes for
functional studies.
3D microtissue interactions: Cell surface bound DNA
oligonucleotides have also allowed the development of 3D
microtissues to control native cell−cell interactions, a current
challenge in the discovery of in vitro tissue models or materials
for in vivo repair. Gartner and Bertozzi demonstrated that
Jurkat cells, possessing different cytosolic dyes, could be
metabolically labeled with N-azidoacetylmannosamine (Man-
NAz) and assembled through surface functionalization with
complementary and noncomplementary phosphine-ssDNA or
difluorinated cyclooctyne (DIFO)-conjugated ssDNA to form
a large aggregate, Figure 7A.140 Microenvironment architecture
including size distribution, structure uniformity, and cell
stoichiometry could be controlled by adjusting cell ratios and
modulating cell−cell assembly rates through altering oligonu-
cleotide sequence complexity and phosphine-DNA labeling
concentrations. Purification of assembled 3D microtissues was
completed with ease by FACS and removal of linkages from
cell−cell junctions was accomplished by heating to 37 °C or
using DNase without disrupting topology. This technology was
adapted to synthesize a functional paracrine signaling network
in 3D, Figure 7B. CHO cells engineered to secret interleukin-3
(IL-3) and untransformed hematopoietic progenitor cell line
(FL5.12), which rely on IL-3 for survival and replication, were
functionalized with complementary DNA to form a 3D tissue
culture within a 3D agarose matrix. Structural growth was
observed as IL-3 accumulated within the microtissue site,
emulating cytokine-dependent immune expansion and tumor
cell proliferation at inflammation sites. In control structures
comprising CHO cells lacking the gene encoding IL-3, the
FL5.12 cells displayed no growth and instead developed
phenotypes consistent with apoptosis. This approach demon-
strates how MOE for DNA aptamer attachment can be used to
investigate cellular communication within microenvironments
with potential to replicate stem cell niche tissue function,
develop high-throughput screening platforms, and recapitulate
human disease (tumor-like phenotypes or differentia-
tion)141,142 as in vitro models.
Concluding remarks: This Viewpoint has summarized the
recent advances in metabolic glycoengineering for the
recruitment of natural and synthetic polymer materials to cell
surfaces. As was the case with polymer−protein conjugation
for the past two decades, the field of cell engineering is moving
Figure 7. Microtissues by DNA conjugation. (A) Metabolic labeling
of Jurkat cells allows cell surface recruitment of complementary
ssDNA to form cell assemblies; (B) Construction of a microtissue
possessing a paracrine signaling network using complementary DNA
strands. CHO cells expressing murine IL-3 (and GFP) supply IL-3 for
growth of murine pro-B cell line FL5.12, whereas in its absence
apoptosis occurs. Figure adapted with permission from 140.
Copyright 2009 NAS.
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from nonspecific methods (and associated challenges of
characterization, heterogeneity, purification) to site-specific
conjugation. Metabolic oligosaccharide engineering enables the
selective introduction of a diverse range of functional handles
to enable the capture of polymeric materials in a convenient
and mild manner, taking advantage of advances in bio-
orthogonal chemistry. This Viewpoint has summarized how
recruitment of synthetic macromolecules to cellular interfaces
has allowed the advancement of (nonexclusively) cell-based
therapies, in vivo cell tracking, biomolecule capture, photo-
thermal therapy, drug delivery, 3D microtissue formation, and
microfabrication. Clearly there is a significant opportunity to
integrate synthetic polymer materials with living systems via
site-selective conjugation methods. This is still an emerging
field, and challenges still remain, including the following: (i)
Balancing cell-surface labeling versus uptake, due to glycan
recycling pathways, to ensure the correct lifetime of labels (or
to promote update where delivery is desired); (ii) Selectively
targeting individual glycans or locations of the glycocalyx; (iii)
In vivo/vitro stability of linkages to ensure robustness over
lifetime of experiments/investigations; (iv) Impact of con-
jugations on cellular function, to ensure they are passive where
desired, but also active and responsive when needed.
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